Unfortunately we don't fully support your browser. If you have the option to, please upgrade to a newer version or use Mozilla Firefox, Microsoft Edge, Google Chrome, or Safari 14 or newer. If you are unable to, and need support, please send us your feedback.
Reaxys combines over a billion chemistry data points with AI to support innovation in drug discovery, chemical R&D and academia. Chemists can quickly access relevant patent, substance and bioactivity insights, and an award-winning retrosynthesis tool.
Break down information silos and accelerate chemistry research
Stay ahead in your field with access to over 113 million documents
With Reaxys' comprehensive patent and journal coverage, chemists can:
Identify new partners and innovation opportunities, from novel drug targets to innovative semiconductor materials
Learn about the latest developments in pharma and chemical research
Gain a deep understanding of the competitive landscape to anticipate and mitigate IP risks
Design new substances and optimize their properties
Reaxys has the largest and most reliable collection of physicochemical, toxicology and bioactivity data to help chemists:
Design novel compounds with improved properties, from target affinity, to conductivity or solubility
Anticipate safety risks, assess the toxicology and ADME profile of compounds
Optimize potency and selectivity of leads with SAR
Accelerate synthesis with access to predicted and published routes
Award-winning predictive retrosynthesis combines high-quality reaction data with AI technology to help chemists:
Plan synthesis with innovative and scientifically robust routes, available in minutes
Analyze and edit reaction steps by reviewing underlying literature references and experimental conditions, all in one view
Select routes to take to the lab based on commercial availability of starting materials
Drive innovation, increase data interoperability
Multidisciplinary teams can work more efficiently by:
Breaking down information silos by making in-house and external data searchable and actionable
Integrating Reaxys data in ELNs and custom applications using Reaxys API
Building knowledge graphs and developing predictive models with off-platform data
Why choose Reaxys for your chemistry research?
113 million documents, 43 million patents
Comprehensive and up-to-date journal and patent coverage from 18,000 journals and 105 patent offices.
283 million substances, 500 million physicochemical data points
Substances from articles, patents and commercial catalogs, including experimental data (NMR, Mass, IR spectra, crystal properties, solubility, etc.)
46 million bioactivities
Normalized bioactivity data points with references (in-vivo and in-vitro toxicity, ADME). SAR analysis with heat map.
Predictive retrosynthesis
Combination of AI technology and 73 million high-quality reactions, including references and experimental procedures.
338 million commercial products
Up-to-date commercial availability of 110 million substances (with price, purity and package size) from 520 suppliers. Option to define preferred vendors.
Off-platform chemical data
Curated chemical data via API and secure data download for search, discovery and predictive modeling applications.
Frequently asked questions
Chemical searches in Reaxys are different due to:
Options for searching structures, reactions, keywords and property values
The unique ability to combine structure and text searches
A transparent query process with an easy-to-follow path to results
You can integrate in-house and external data in a proprietary version of Reaxys. Critical in-house knowledge becomes searchable and actionable. This seamless integration sets Reaxys apart from other chemistry research solutions.
Reaxys includes:
Organic, inorganic and organometallic substances
Chemical reactions
Published experimental facts, including substance property, spectral and reaction data
Chemical patents
Yes, Reaxys has the largest collection of new pharma and chemical patents from 105 patent offices. Titles, abstracts and claims are translated to English. Fastest access to substances in newly published patents — only five days after publication